Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: Results from SWOG 0421

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Lara, Primo N ^a,i   Ely, Benjamin ^b   Quinn, David I ^c   Mack, Philip C ^a   Tangen, Catherine ^b   Gertz, Erik ^d   Twardowski, Przemyslaw W ^e   Goldkorn, Amir ^c   Hussain, Maha ^f   Vogelzang, Nicholas J ^g   Thompson, Ian M ^h   Van Loan, Marta D ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g US Oncology ^*  (United States)

^h UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ATRASENTAN; CARBOXY TERMINAL COLLAGEN PROPETIDE; COLLAGEN; DOCETAXEL; PLACEBO; PREDNISONE; PYRIDINOLINE; TUMOR MARKER; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; AMINO ACID; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; ENDOTHELIN A RECEPTOR; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; PYRROLIDINE DERIVATIVE; TAXOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OSTEOLYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; SURVIVAL TIME; BLOOD; BONE REMODELING; BONE TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; AMINO ACIDS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BONE REMODELING; COLLAGEN TYPE I; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; ROC CURVE; TAXOIDS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84898885627     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju013     Document Type: Article

References (26)

1. Pollen JJ, Gerber K, Ashburn WL, et al. Nuclear bone imaging in meta-static cancer of the prostate. Cancer. 1981;47(11):2585-2594.
2. Maeda H, Koizumi M, Yoshimura K, et al. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997;157(2):539-543.
3. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000;88(12 suppl):295-2960.
4. Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol. 2004;15(3):455-459.
5. Lara PN Jr, Stadler WM, Longmate J, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006;12(5):1556-1563.
6. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959-1966.
7. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113(9):2478-2487.
8. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3(2):110-116.
9. Nelson JB, Lee WH, Nguyen SH, et al. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997;57(1):35-37.
10. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003;100(19):10954-10959.
11. Mundy GR. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci USA. 2003;100(19):10588-10589.
12. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003;9(7):2587-2597.
13. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44(1):77-87.
14. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14(9):893-900.
15. Sano M, Kushida K, Takahashi M, et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Brit J Cancer. 1994;70(4):701-703.
16. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phos-phatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80(1):97-103.
17. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-344.
18. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem. 1995; 41(10):1489-1494.
19. Houze P, Bellik B, Extra JM, et al. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin Chim Acta. 1999;281(1-2):77-88.
20. Blomqvist C, Risteli L, Risteli J, et al. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metas-tases from breast carcinoma. Brit J Cancer. 1996;73(9):1074-1079.
21. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Brit J Cancer. 1996;73(12):1581-1587.
22. Takeuchi S, Arai K, Saitoh H, et al. Urinary pyridinoline and deoxypyri-dinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996;156(5):1691-1695.
23. Yoshida K, Sumi S, Arai K, et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer. 1997;80(9):1760-1767.
24. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12(11 Pt 1):3361-3367.
25. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925-4935.
26. Som A, Tu SM, Liu J, et al. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Brit J Cancer. 2012;107(9):1547-1553.